Nakamura, Tomonori

写真a

Affiliation

Faculty of Pharmacy, Department of Pharmacy 医療薬学・社会連携センター 医療薬学部門 (Shiba-Kyoritsu)

Position

Professor

External Links

Career 【 Display / hide

  • 1993.04
    -
    1997.03

    Faculty of Pharmaceutical Sicences, Chiba University, Laboratory of Natural Products Chemistry, Reasearch Assistant

  • 1997.04
    -
    1997.06

    Faculty of Pharmaceutical Sciences, Chiba University, Laboratory of Natural Products Chemistry, Research Associate

  • 1997.07
    -
    1999.03

    Center for Basic Sciences, Kitasato Institute, 微生物薬品化学研究室, Post Doctral Fellow (JSPS PosDoc Fellow)

  • 1999.04
    -
    2005.03

    Chiba University Graduate School of Pharmaceutical Sciences, Department of Clinical Pharmacology & Pharmacotherapeutics, Assitant Professor

  • 2005.04
    -
    2007.03

    Chiba University Graduate School of Pharmaceutical Sciences, Department of Clinical Pharmacology & Pharmacotherapeutics, Associate Professor

display all >>

Academic Background 【 Display / hide

  • 1985.04
    -
    1989.03

    Nihon University, Faculty of Science and Engineering, School of Pharmacy

    University, Graduated

  • 1989.04
    -
    1991.03

    Chiba University, Graduate School of Pharmaceutical Sciences, Department of Natural Products

    Graduate School, Completed, Master's course

  • 1991.04
    -
    1993.03

    Chiba University, Graduate School of Pharmaceutical Sciences, Department of Natural Products

    Graduate School, Withdrawal before completion, Doctoral course

Academic Degrees 【 Display / hide

  • Ph.D. in Pharmaceutical Sciences, Chiba University, Dissertation, 1997.05

    和漢薬・民間伝承薬由来の向神経活性成分に関する化学的・薬理学的研究

Licenses and Qualifications 【 Display / hide

  • Pharmacist, 1989.09

  • 日本医療薬学会指導薬剤師, 2007.01

  • 日本臨床薬理学会指導薬剤師, 2018.10

  • 日本医療薬学会認定薬剤師, 2005.01

 

Research Areas 【 Display / hide

  • Life Science / Clinical pharmacy (Clinical Pharmaceutical Science)

Research Keywords 【 Display / hide

  • personalized drug therapy

  • molecular diabetology

  • education of clinical pharmacy

  • kampo medicine/herbal medicine

  • clinical pharmacology

Research Themes 【 Display / hide

  • 和漢薬・生薬の適正使用の推進と薬効薬理メカニズムの解析, 

    2013.04
    -
    Present

  • 医療薬学に関連した薬学教育の洗練化, 

    2013.04
    -
    Present

  • 薬剤抵抗性の発現機構解明と薬動力学解析に基づく個別化薬物治療法の構築, 

    2013.04
    -
    Present

 

Books 【 Display / hide

  • フィジカルアセスメントに基づく症例解析と薬物治療

    大林恭子、中村智徳 編著, 京都廣川書店, 2021.08

  • 今日のOTC薬 改訂第5版

    伊東明彦、中村智徳 編, 南江堂, 2021.02

  • 現代医療における漢方薬 改訂第3版

    NAKAMURA Tomonori, 南江堂, 2020.02,  Page: 175

    Scope: 第7章 漢方薬の服薬指導,  Contact page: 121-135

  • NEO 薬学シリーズ12 早期臨床体験テキスト

    NAKAMURA Tomonori, ネオメディカル, 2017.03

    Scope: 第10章 調剤の基礎を体験する

  • 現代医療における漢方薬 改訂第2版

    NAKAMURA Tomonori, 南江堂, 2016.01

    Scope: 第7章 漢方薬の服薬指導

display all >>

Papers 【 Display / hide

  • Patient-Associated Risk Factors for Severe Anemia in Patients with Advanced Ovarian or Breast Cancer Receiving Olaparib Monotherapy: A Multicenter Retrospective Study

    Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Kawasaki T, Furukawa T, Nakamura T

    Frontiers in Oncology (Frontiers Media SA)  12   898150 2022.10

    Research paper (scientific journal), Joint Work, Last author, Accepted

  • Design, Synthesis, and Monoamine Oxidase B Selective Inhibitory Activity of N-Arylated Heliamine Analogues.

    Yamada Makito, Hirose Yu, Lin Bangzhong, Fujimoto Megumi, Nunomura Kazuto, Sirimangkalakitti Natchanun, Takahashi Naoyuki, Ohki, Yuuta, Sako Makoto, Murai Kenichi, Harada Kazuo, Arai Masayoshi, Suzuki Sayo, Nakamura Tomonori, Haruta Junichi, Arisawa Mitsuhiro

    ACS Medicinal Chemistry Letters (American Chemical Society)  13   1582 - 1590 2022.08

    Research paper (scientific journal), Joint Work, Accepted

  • Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography–Photodiode array detection

    Yuta Yokoyama, Eiji Nozawa, Miho Morita, Emi Ishikawa, Takehiko Mori, Masatoshi Sakurai, Taku Kikuchi, Eri Matsuki, Rie Yamazaki, Keisuke Kataoka, Aya Jibiki, Hitoshi Kawazoe, Sayo Suzuki, Tomonori Nakamura

    J Clin Lab Anal (Wiley)  36 ( 8 ) e24598 2022.07

    Research paper (scientific journal), Joint Work, Last author, Accepted

  • Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum

    Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Ouki Kuniyoshi, Itaru Sato, Naoki Nakaya, Hideo Nakajima, Motonori Kimura, Jun Hakamata, Naoya Suehiro, Hideo Nakada, Shinnosuke Ikemura, Aya Jibiki, Hitoshi Kawazoe, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura

    J Chromatogr B Analyt Technol Biomed Life Sci (Elsevier)  1199   123245 2022.05

    Research paper (scientific journal), Joint Work, Last author, Accepted,  ISSN  15700232

     View Summary

    Reports on the therapeutic drug monitoring (TDM) of second- and third-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer patients are limited and are required to improve the safety of EGFR-TKI therapy. Some EGFR-TKIs have active metabolites with similar or higher potency compared with the parent compounds; thus, monitoring the parent compound as well as its active metabolites is essential for truly effective TDM. In this study, we developed and validated a method that simultaneously quantifies second- and third-generation EGFR-TKIs (afatinib, dacomitinib, and osimertinib) and the active metabolites of osimertinib, AZ5104 and AZ7550, in the human serum using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The clinical application of the method was also evaluated. The analytes were extracted from a 100 μL serum sample using a simple protein precipitation method and analyzed using LC-MS/MS. Excellent linearity of calibration curves was observed at ranges of 2.5–125.0 ng/mL for afatinib, 2.5–125.0 ng/mL for dacomitinib, 4.0–800.0 ng/mL for osimertinib, 1.0–125.0 ng/mL for AZ5104, and 2.5–125.0 ng/mL for AZ7550. The precision and accuracy were below 14.9% and within ± 14.9% of the nominal concentrations, respectively. The mean recovery was higher than 94.7% and the coefficient of variation (CV) was lower than 8.3%. The mean internal-standard normalized matrix factors ranged from 94.6 to 111.9%, and the CVs were lower than 9.7%. This analytical method met the acceptance criteria of the U.S. Food and Drug Administration guidelines. The method was also successfully applied to the analysis of 45 clinical samples; it supports the efficient and valuable analysis for TDM investigations of EGFR-TKIs.

  • Prognostic Value of Baseline Medications plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients with Advanced Non-Small-Cell Lung Cancer: A Retrospective Study

    Ogiwara T, Kawazoe H, Egami S, Hashimoto H, Saito Y, Sakiyama N, Ohe Y, Yamaguchi M, Furukawa T, Hara A, Hiraga Y, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T

    Frontiers in Oncology (Frontiers Media SA)  11   770268 2021.11

    Research paper (scientific journal), Joint Work, Last author, Accepted

     View Summary

    Background: Nivolumab and pembrolizumab are the standard treatments for patients with advanced non-small-cell lung cancer (NSCLC). While there are reports on several inflammatory indices and the prognosis of patients with cancer, no study has combined baseline medication with the neutrophil-to-lymphocyte ratio (NLR) to predict clinical outcomes. This study investigated the efficacy of baseline medications plus NLR to predict the effectiveness of nivolumab and pembrolizumab in a real-world clinical setting. Methods: We conducted a single-center retrospective observational study of consecutive patients with advanced NSCLC who received nivolumab or pembrolizumab as first-line, second-line, or beyond treatment between December 2015 and November 2018 at the National Cancer Center Hospital in Japan. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method. The drug-based prognostic score for baseline medications plus NLR was weighed based on the regression β coefficients. The multivariable Cox proportional hazard model was used to assess the association between the prognostic score-stratified groups and survival outcomes. Results: In total, 259 patients were evaluated in this study. A prognostic score calculated from the baseline medications plus NLR was used to categorize the patients into good (score 0), intermediate (scores 1–2), and poor (scores 3–6) -prognosis groups. The multivariable Cox proportional hazard model revealed a significant association between the poor-prognosis group and reduced OS. The hazard ratio of OS was 1.75 (95% confidence interval: 1.07–2.99; P = 0.031). In contrast, no association between these prognosis groups and PFS was observed. Conclusions: The findings suggest that the baseline medications with nivolumab or pembrolizumab plus NLR could lead to progressively shorter survival outcomes in patients with advanced NSCLC and could be used as a prognostic index for poor outcomes. However, to ascertain the clinical application of these findings, these concomitant medications need further validation in a large-scale multicenter study.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Reviews, Commentaries, etc. 【 Display / hide

  • 一般的な薬物と免疫チェックポイント阻害薬の体内動態~薬物は体内でどのような運命をたどって効果を発揮し体内から消失していくのか~

    鈴木小夜,中村智徳

    がん看護 (南江堂)  27 ( 2 ) 200 - 205 2022.02

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

  • 免疫チェックポイント阻害薬の体内動態と有効性/毒性との関係

    鈴木小夜,中村智徳

    がん看護 (南江堂)  27 ( 2 ) 206 - 212 2022.02

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Joint Work

  • LC-MS/MSを用いた第二、三世代EGFR-TKI未変化体及び活性代謝物の血清中濃度同時測定法の構築と臨床に向けた検討

    石川恵海, 横山雄太, 千島陽奈, 国吉央城, 佐藤 到, 中谷直喜, 中島日出夫, 木村元範, 袴田 潤, 末廣直哉, 中田英夫, 池村辰之介, 平賀ゆい, 地引 綾, 河添 仁, 村松 博, 鈴木小夜, 中村智徳

    TDM研究 (日本TDM学会)  38 ( 2 ) 187 2021.05

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work,  ISSN  0911-1026

  • Outcomes of clinical pharmacy research aimed at avoiding or reducing cancer chemotherapy-induced adverse reaction

    Hitoshi Kawazoe, Tomonori Nakamura

    医療薬学 (日本医療薬学会)  46 ( 9 ) 467 - 480 2020.09

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • Recent studies related to side effects of Kampo medicines; Analysis of glycyrrhizic acid metabolites in patients suspected of psedoaldosteronism

    中村智徳、吉野鉄大、堀場裕子、渡辺賢治、三村 將、小川恵子、南澤 潔、並木隆雄、牧野利明

    医薬品相互作用研究 (医薬品相互作用研究会)  44 ( 2 ) 6 - 17 2020.06

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

display all >>

Presentations 【 Display / hide

  • Kampo medicines to be effective against obesity and the intestinal flora

    Tomonori Nakamura

    International Exchange Conference on Recent Advances in Basic and Clinical Research of Fatty liver disease, 

    2022.10

    Symposium, workshop panel (nominated), Jinshan District Medical Association of Traditional Chineses Medicine Group

  • 抗肥満作用を有する漢方薬の薬効と腸内細菌叢構成の関連性の検討

    仲道公輔,地引 綾,横山雄太,河添 仁,鈴木小夜,吉野鉄大,渡辺賢治,秋山雅博,金 倫基,中村智徳

    第3回和漢医薬学会若手研究者フォーラム, 

    2022.08

    Oral presentation (general)

  • COVID-19 パンデミック下での実務実習は薬局実務実習生のプロフェッショナリズムに 影響をもたらしたのか

    松野 昂樹、鈴木 小夜、牧山 大輝、地引 綾、横山 雄太、河添 仁 、中村 智徳

    第7回日本薬学教育学会大会, 

    2022.08

    Oral presentation (general)

  • Novel Assay for Simultaneous Quantification of Parent Compounds and Active Metabolites of Second-/third-generation EGFR-TKIs for Clinical Application

    Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Ouki Kuniyoshi, Itaru Satou, Naoki Nakaya, Hideo Nakajima, Hideo Nakada, Motonori Kimura, Jun Hakamata, Naoya Suehiro, Shinnosuke Ikemura, Aya Jibiki, Hitoshi Kawazoe, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura

    The 21st Asian Conference on Clinical Pharmacy: ACCP 2022 in Nagoya (Nagoya) , 

    2022.02

    Symposium, workshop panel (public)

  • Ingenol Mebutate Inhibits Proliferation of Pancreatic Cancer Cells at Lower Concentration than Other Established Antitumor Agents for Pancreatic Cancer

    Fumihiro Kikuyama, Sayo Suzuki, Haruka Yoshioka, Yu Hirose, Yuta Yokoyama, Aya Jibiki, Hitoshi Kawazoe, Tomonori Nakamura

    The 21st Asian Conference on Clinical Pharmacy 2022 in Nagoya (Nagoya) , 

    2022.02

    Poster presentation

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 和漢薬と西洋薬との併用における適正使用に向けた臨床薬理学的研究

    2013.04
    -
    2017.03

    日本学術振興会, Grant-in-Aid for Scientific Research, NAKAMURA, Tomonori, Research grant, Principal investigator

     View Summary

    実臨床での和漢薬と西洋薬との併用事例を検証し、東西医薬の併用に関する適正性の検証および有効性の科学的根拠と有害事象の発生を回避する指標の確立を目的とする。本研究期間内に、①当医療施設過去1~3 年間の全処方から西洋薬と和漢薬との併用事例を抽出し、その処方意図および有効性・安全性に関する事例をカルテ調査する。②無効例や有害事例での西洋薬の薬物動態に与える和漢薬の影響を精査する。③併用事例の有効性に関する実験薬理学的検証を行う。

  • アルコール含有抗がん薬投与時の自動車運転動作への影響の検討

    2013.04
    -
    2014.03

    全国共済農業協同組合連合会JA共済, 平成25年度JA共済交通事故医療研究助成, Research grant, Principal investigator

     View Summary

    抗がん薬の中にはアルコールを含有する製剤が存在し、単身乗用車で通院した際に自動車運転に影響を及ぼす可能性があり、帰宅前に迅速にアルコール血中濃度を測定し、自動車運転の可否を判断する方法を確立する必要がある。そこで本研究では、アルコール含有抗がん薬の投与を受けた患者の呼気中濃度と血中濃度との相関性を明らかにし、自動車運転動作への影響を検討する。

  • 実務実習における薬学生の薬学的介入に関する実態調査

    2013.04
    -
    2014.03

    Keio University, Keio Gijuku Academic Development Funds, NAKAMURA, Tomonori, Research grant, Principal investigator

     View Summary

    本学部5年次の病院・薬局実務実習を通じて経験した、薬物治療における未解決の臨床的課題に対する薬学的介入の有効性についての検証を目的として、以下の3点について検討した。
    ① OTC薬実習の実習内容に関する調査研究
    ② 実務実習での薬学生の服薬指導・コミュニケーションスキルの検証
    ③ 実務実習での薬学生の点眼薬服薬指導の有効性に関する検証

  • 生物学的製剤のリウマチ治療効果予測モデルの構築

    2014.04
    -
    2015.03

    公益財団法人 上原記念生命科学財団, 上原記念生命科学財団 平成25年度研究助成金, Research grant, Principal investigator

     View Summary

    関節リウマチ(RA)、全身性エリテマトーデス(SLE)等自己免疫疾患の薬物治療において大きな課題である「治療抵抗性」の克服に向けて、治療薬及びその代謝産物の体内動態と治療効果との相関性について検討することにより、薬動力学的解析に基づく適切な薬物療法支援システムの構築を目的とする。

  • 治療抵抗性リウマチ性疾患に対する個別化薬物治療に向けた臨床薬理学的研究

    2014.04
    -
    2015.03

    公益財団法人 薬学研究奨励財団, 第33回薬学研究奨励財団研究助成金, Research grant, Principal investigator

     View Summary

    全身性血管炎、全身性エリテマトーデスおよびリウマチ性疾患などの難治性自己免疫疾患の治療には主にステロイド剤や免疫抑制剤などが盛んに用いられている。しかし、これらの薬剤に対する抵抗性の発現により疾患制御が困難な症例が存在するが、その原因究明が十分に行われておらず、臨床上重要な課題となっている。そこで本研究ではステロイド応答性の個人差を規定する生体内因子を解明し、ステロイド抵抗性の改善策の確立を目的とする。

Awards 【 Display / hide

  • 日本臨床腫瘍薬学会学術大会2019優秀演題賞

    河添 仁, 亀井義明, 村上朱里, 山下美智子, 薬師神芳洋, 中村智徳, 2019.03, 日本臨床腫瘍薬学会, 標準制吐療法下における乳がんアンスラサイクリン誘発悪心・嘔吐の患者関連リスク因子

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第59回日本薬学会関東支部大会 優秀ポスター賞

    羽田有里, 青森達, 坡下真大, 荒木拓也, 山本康次郎, 鈴木小夜, 地引綾, 中村智徳, 2015.09, 日本薬学会関東支部, アプレピタントによる補助療法ががん化学療法の治療経過に与える影響

    Type of Award: Award from Japanese society, conference, symposium, etc.

  • 第66回日本食道学会学術集会優秀ポスター演題賞(メディカルスタッフ)

    荒木聖美、長嶺 歩、青森 達、荒木拓也、飯塚恵子、田中成岳、浅尾高行、桑野博行、中村智徳、山本康次郎., 2012.06, 日本食道学会, 食道癌化学放射線療法における免疫栄養剤併用の有用性.

  • 医療薬学フォーラム2010 第18回クリニカルファーマシーシンポジウム優秀ポスター賞

    "伊藤真理恵, 秋好健志, 村瀬沙織, 宮崎光江, 中村克徳, 中村智徳, Guengerich F, Peter, 山本康次郎, 大谷壽一.", 2010.07, 日本薬学会, CYP3A4変異型分子種の代謝活性に対する阻害剤の阻害強度の比較.

  • Journal of Natural Medicines優秀論文賞2007

    Tomonori Nakamura, Nobuko Komai, Issei Isogami, Koichi Ueno, Fumio Ikegami, Kageyoshi Ono, Shingo Yano, 2007.09, The Japanese Society of Pharmacognosy, Memory and learnig-enhancing effect of Daikenchuto, a traditional Japanese herbal medicine, in mice

display all >>

 

Courses Taught 【 Display / hide

  • ADVANCED PRACTICAL TRAINING IN A HOSPITAL

    2022

  • ADVANCED PRACTICAL TRAINING IN A HOSPITAL (ABROAD)

    2022

  • STUDY OF MAJOR FIELD: (PHARMACEUTICAL CARE SCIENCES)

    2022

  • SEMINAR: (PHARMACEUTICAL CARE SCIENCES)

    2022

  • RESEARCH FRONTIERS IN BIOMEDICAL SCIENCE

    2022

display all >>

Courses Previously Taught 【 Display / hide

  • 早期体験学習(薬学科)

    Keio University

    2020.04
    -
    2021.03

    Spring Semester, Seminar, Within own faculty, 3h

    薬剤師の職能、病院・薬局見学、調剤体験、BLS実習、車いす・高齢者疑似体験

  • 実務実習事前学習

    Keio University

    2020.04
    -
    2021.03

    Autumn Semester, Laboratory work/practical work/exercise, Within own faculty, 164people

  • 病院実務実習

    Keio University

    2018.04
    -
    2019.03

    Full academic year, Laboratory work/practical work/exercise, Within own faculty, 151people

  • 薬局実務実習

    Keio University

    2018.04
    -
    2019.03

    Full academic year, Laboratory work/practical work/exercise, Within own faculty, 151people

  • D1病院・薬局に行く前にB

    Keio University

    2017.04
    -
    2018.03

    Autumn Semester, Lecture, Within own faculty, 164people

    医薬品の管理・供給、リスクマネージメント、処方解析

display all >>

Educational Activities and Special Notes 【 Display / hide

  • 早期臨床体験テキスト NEO薬学シリーズ12

    2017.03

    , Development of Textbook and Teaching Material

  • 現代医療における漢方薬 改訂第2版

    2016.01

    , Development of Textbook and Teaching Material

     View Details

    第7章 漢方薬の服薬指導

  • NEO薬学シリーズ3 Principal Pharmacotherapy

    2015.06

    , Development of Textbook and Teaching Material

     View Details

    第1部 身体の病的変化を知る 医薬品の安全性

  • 女性とくすりQ&A 患者に適した薬剤選択のために

    2008.09

    , Development of Textbook and Teaching Material

     View Details

    Ⅲ章 漢方、代替医療、サプリメント

  • ファーマコセラピー 病態生理からのアプローチ

    2007.08

    , Development of Textbook and Teaching Material

     View Details

    第51章 酸塩基平衡異常

 

Memberships in Academic Societies 【 Display / hide

  • 日本医薬品安全性学会, 

    2015
    -
    Present
  • American Society of Pharmacology & Experimental Therapeutics, 

    2011
    -
    Present
  • 日本薬物動態学会, 

    2009
    -
    Present
  • 日本臨床薬理学会, 

    2008
    -
    Present
  • 日本糖尿病学会, 

    2007
    -
    Present

display all >>

Committee Experiences 【 Display / hide

  • 2021.04
    -
    Present

    関東地区調整機構委員長, 薬学教育協議会

  • 2017.04
    -
    Present

    関東地区調整機構委員, 薬学教育協議会

  • 2017.01
    -
    2017.11

    第27回日本医療薬学会年会 実行委員, 日本医療薬学会

  • 2016.04
    -
    Present

    学術評議員, 日本薬理学会

  • 2016.04
    -
    2019.03

    学術雑誌編集委員, 日本薬学会

display all >>